4//SEC Filing
Burstein Jennifer 4
Accession 0001567619-18-007785
CIK 0001581720other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:14 PM ET
Size
28.2 KB
Accession
0001567619-18-007785
Insider Transaction Report
Form 4
Burstein Jennifer
Vice President of Finance
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-12-10−1,250→ 18,750 totalExercise: $11.35Exp: 2025-04-30→ Common Stock (1,250 underlying) - Exercise/Conversion
Common Stock
2018-12-10$11.35/sh+1,250$14,188→ 1,250 total - Sale
Common Stock
2018-12-10$130.79/sh−100$13,079→ 1,150 total - Sale
Common Stock
2018-12-10$132.44/sh−400$52,976→ 750 total - Sale
Common Stock
2018-12-10$133.34/sh−100$13,334→ 650 total - Sale
Common Stock
2018-12-10$134.71/sh−550$74,091→ 100 total - Sale
Common Stock
2018-12-10$136.04/sh−100$13,604→ 0 total - Exercise/Conversion
Common Stock
2018-12-11$11.35/sh+1,250$14,188→ 1,250 total - Sale
Common Stock
2018-12-11$135.69/sh−200$27,138→ 1,050 total - Sale
Common Stock
2018-12-11$136.98/sh−587$80,407→ 463 total - Sale
Common Stock
2018-12-11$137.88/sh−263$36,262→ 200 total - Sale
Common Stock
2018-12-11$139.36/sh−100$13,936→ 100 total - Sale
Common Stock
2018-12-11$140.48/sh−100$14,048→ 0 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-12-11−1,250→ 17,500 totalExercise: $11.35Exp: 2025-04-30→ Common Stock (1,250 underlying)
Footnotes (8)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents the aggregate of sales effected on the same day at different prices.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.20 to $132.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.40 to $135.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.28 to $136.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.50 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, May 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments.
Documents
Issuer
Loxo Oncology, Inc.
CIK 0001581720
Entity typeother
Related Parties
1- filerCIK 0001640069
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 5:14 PM ET
- Size
- 28.2 KB